These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23360137)

  • 1. Memory restored in Alzheimer’s disease brain cells: the compound AC253, originally designed to target diabetes, appears to restore memory.
    Parks L
    Future Med Chem; 2013 Feb; 5(2):121. PubMed ID: 23360137
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the CREB pathway for memory enhancers.
    Tully T; Bourtchouladze R; Scott R; Tallman J
    Nat Rev Drug Discov; 2003 Apr; 2(4):267-77. PubMed ID: 12669026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystatin C: a potential target for Alzheimer's treatment.
    Levy E
    Expert Rev Neurother; 2008 May; 8(5):687-9. PubMed ID: 18457524
    [No Abstract]   [Full Text] [Related]  

  • 4. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
    J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential therapeutic targets in the NF-kappaB pathway for Alzheimer's disease.
    Collister KA; Albensi BC
    Drug News Perspect; 2005 Dec; 18(10):623-9. PubMed ID: 16491164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hidden talents. Proteins implicated in Alzheimer's disease also coddle brain cells.
    Leslie M
    Sci Aging Knowledge Environ; 2004 Apr; 2004(14):nf38. PubMed ID: 15071176
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroprotective effect of Alpinia galanga (L.) fractions on Aβ(25-35) induced amnesia in mice.
    Hanish Singh JC; Alagarsamy V; Diwan PV; Sathesh Kumar S; Nisha JC; Narsimha Reddy Y
    J Ethnopharmacol; 2011 Oct; 138(1):85-91. PubMed ID: 21911048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A system for the brain-enhanced delivery of estradiol: an assessment of its potential for the treatment of Alzheimer's disease and stroke.
    Simpkins JW; Rabbani O; Shi J; Panickar KS; Green PS; Day AL
    Pharmazie; 1998 Aug; 53(8):505-11. PubMed ID: 9741059
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer's disease.
    Hampel H; Prvulovic D; Teipel SJ; Bokde AL
    Prog Neurobiol; 2011 Dec; 95(4):570-8. PubMed ID: 21777651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's Disease, time to turn the tide.
    Sensi SL
    Aging (Albany NY); 2018 Oct; 10(10):2537-2538. PubMed ID: 30317224
    [No Abstract]   [Full Text] [Related]  

  • 12. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.
    Roher AE; Kokjohn TA
    Alzheimers Dement; 2009 Sep; 5(5):437-8. PubMed ID: 19751925
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic compliance of nanomedicine in Alzheimer's disease.
    Wilson B
    Nanomedicine (Lond); 2011 Sep; 6(7):1137-9. PubMed ID: 21929451
    [No Abstract]   [Full Text] [Related]  

  • 15. Simvastatin enhances learning and memory independent of amyloid load in mice.
    Li L; Cao D; Kim H; Lester R; Fukuchi K
    Ann Neurol; 2006 Dec; 60(6):729-39. PubMed ID: 17192930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
    Fisher A
    Neurodegener Dis; 2008; 5(3-4):237-40. PubMed ID: 18322400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DHEAS improves learning and memory in aged SAMP8 mice but not in diabetic mice.
    Farr SA; Banks WA; Uezu K; Gaskin FS; Morley JE
    Life Sci; 2004 Oct; 75(23):2775-85. PubMed ID: 15464829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatments and therapeutic targets in Alzheimer's disease.
    Zlokovic BV
    Adv Drug Deliv Rev; 2002 Dec; 54(12):1533-7. PubMed ID: 12453670
    [No Abstract]   [Full Text] [Related]  

  • 19. [Progress in the research on multi-target-directed drugs against Alzheimer's disease].
    Liu RT; Lü QJ
    Yao Xue Xue Bao; 2009 Mar; 44(3):258-63. PubMed ID: 19449521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research design issues: antialuminum drug studies in Alzheimer's disease.
    Shore D; Wyatt RJ
    Clin Neuropharmacol; 1982 Dec; 5(4):337-43. PubMed ID: 7159877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.